

# i-STAT EC8+ Cartridge

Intended for use with the i-STAT 1 Analyzer (REF 04P75-01 & 03P75-06)



## NAME

i-STAT EC8+ Cartridge – REF 03P79-25

## INTENDED USE

The i-STAT EC8+ cartridge with the i-STAT 1 System is intended for use in the *in vitro* quantification of sodium, potassium, chloride, glucose, blood urea nitrogen, hematocrit, pH and carbon dioxide partial pressure in arterial, venous, or capillary whole blood.

Analyte	Intended Use
Sodium (Na)	Sodium measurements are used for monitoring electrolyte imbalances.
Potassium (K)	Potassium measurements are used in the diagnosis and monitoring of diseases and clinical conditions that manifest high and low potassium levels.
Chloride (Cl)	Chloride measurements are primarily used in the diagnosis, monitoring, and treatment of electrolyte and metabolic disorders including, but not limited to, cystic fibrosis, diabetic acidosis, and hydration disorders.
Glucose (Glu)	Glucose measurements are used in the diagnosis, monitoring, and treatment of carbohydrate metabolism disorders including, but not limited to, diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and pancreatic islet cell carcinoma.
Blood Urea Nitrogen (BUN/Urea)	Blood urea nitrogen measurements are used for the diagnosis, monitoring, and treatment of certain renal and metabolic diseases.
Hematocrit (Hct)	Hematocrit measurements can aid in the determination and monitoring of normal or abnormal total red cell volume status including, but not limited to, conditions such as anemia, erythrocytosis, and blood loss related to trauma and surgery.
pH	pH, and $PCO_2$ measurements are used in the diagnosis, monitoring, and treatment of respiratory disturbances and metabolic and respiratory-based acid-base disturbances.
Carbon Dioxide Partial Pressure ( $PCO_2$ )	Bicarbonate is used in the diagnosis and treatment of numerous potentially serious disorders associated with changes in body acid-base balance.

## **SUMMARY AND EXPLANATION/CLINICAL SIGNIFICANCE**

### **Measured:**

#### **Sodium (Na)**

Tests for sodium in the blood are important in the diagnosis and treatment of patients suffering from hypertension, renal failure or impairment, cardiac distress, disorientation, dehydration, nausea and diarrhea. Some causes of increased values for sodium include dehydration, diabetes insipidus, salt poisoning, skin losses, hyperaldosteronism and CNS disorders. Some causes for decreased values for sodium include dilutional hyponatremia (cirrhosis), depletion hyponatremia and syndrome of inappropriate ADH.

#### **Potassium (K)**

Tests for potassium in the blood are important in the diagnosis and treatment of patients suffering from hypertension, renal failure or impairment, cardiac distress, disorientation, dehydration, nausea and diarrhea. Some causes of increased values for potassium include renal glomerular disease, adrenocortical insufficiency, diabetic ketoacidosis (DKA), sepsis and *in vitro* hemolysis. Some causes of decreased values for potassium include renal tubular disease, hyperaldosteronism, treatment of DKA, hyperinsulinism, metabolic alkalosis and diuretic therapy.

#### **Chloride (Cl)**

Tests for chloride in the blood are important in the diagnosis and treatment of patients suffering from hypertension, renal failure or impairment, cardiac distress, disorientation, dehydration, nausea and diarrhea. Some causes of increased values for chloride include prolonged diarrhea, renal tubular disease, hyperparathyroidism and dehydration. Some causes for decreased values for chloride include prolonged vomiting, burns, salt-losing renal disease, overhydration and thiazide therapy.

#### **Glucose (Glu)**

Glucose is a primary energy source for the body and the only source of nutrients for brain tissue. Measurements for determination of blood glucose levels are important in the diagnosis and treatment of patients suffering from diabetes and hypoglycemia. Some causes for increased values of glucose include diabetes mellitus, pancreatitis, endocrine disorders (e.g., Cushing's syndrome), drugs (e.g., steroids, thyrotoxicosis), chronic renal failure, stress, or I.V. glucose infusion. Some causes of decreased values of glucose include insulinoma, adrenocortical insufficiency, hypopituitarism, massive liver disease, ethanol ingestion, reactive hypoglycemia, and glycogen storage disease.

#### **Blood Urea Nitrogen (BUN/Urea)**

An abnormally high level of urea nitrogen in the blood is an indication of kidney function impairment or failure. Some other causes of increased values for urea nitrogen include prerenal azotemia (e.g., shock), postrenal azotemia, GI bleeding and a high protein diet. Some causes of decreased values for urea nitrogen include pregnancy, severe liver insufficiency, overhydration and malnutrition.

### Hematocrit (Hct)

Hematocrit is a measurement of the fractional volume of red blood cells. This is a key indicator of the body's state of hydration, anemia or severe blood loss, as well as the blood's ability to transport oxygen. A decreased hematocrit can be due to either overhydration, which increases the plasma volume, or a decrease in the number of red blood cells caused by anemias or blood loss. An increased hematocrit can be due to loss of fluids, such as in dehydration, diuretic therapy, and burns, or an increase in red blood cells, such as in cardiovascular and renal disorders, polycythemia vera, and impaired ventilation.

### pH

pH is an index of the acidity or alkalinity of the blood with an arterial pH of <7.35 indicating an acidemia and >7.45 alkalemia. <sup>1</sup>

### Carbon Dioxide Partial Pressure (PCO<sub>2</sub>)

PCO<sub>2</sub> along with pH is used to assess acid-base balance. PCO<sub>2</sub> (partial pressure of carbon dioxide), the respiratory component of acid-base balance, is a measure of the tension or pressure of carbon dioxide dissolved in the blood. PCO<sub>2</sub> represents the balance between cellular production of CO<sub>2</sub> and ventilatory removal of CO<sub>2</sub> and a change in PCO<sub>2</sub> indicates an alteration in this balance. Causes of primary respiratory acidosis (increase in PCO<sub>2</sub>) are airway obstruction, sedatives and anesthetics, respiratory distress syndrome, and chronic obstructive pulmonary disease. Causes of primary respiratory alkalosis (decreased PCO<sub>2</sub>) are hypoxia (resulting in hyperventilation) due to chronic heart failure, edema and neurologic disorders, and mechanical hyperventilation.

## TEST PRINCIPLE

The i-STAT System uses direct (undiluted) electrochemical methods. Values obtained by direct methods may differ from those obtained by indirect (diluted) methods. <sup>2</sup>


### Measured:

#### Sodium (Na), Potassium (K) and Chloride (Cl)

The respective analyte is measured by ion-selective electrode potentiometry. Concentrations are calculated from the measured potential through the Nernst equation.


#### Glucose (Glu)

Glucose is measured amperometrically. Oxidation of glucose, catalyzed by the enzyme glucose oxidase, produces hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). The liberated H<sub>2</sub>O<sub>2</sub> is oxidized at the electrode to produce a current proportional to the sample glucose concentration.



#### BUN/Urea

Urea is hydrolyzed to ammonium ions in a reaction catalyzed by the enzyme urease.



The ammonium ions are measured potentiometrically by an ion-selective electrode. In the calculation of results, concentration is related to potential through the Nernst Equation.

**Hematocrit (Hct)**

Hematocrit is determined conductometrically. The measured conductivity, after correction for electrolyte concentration, is inversely related to the hematocrit.

**pH**

pH is measured by direct potentiometry. In the calculation of results for pH, concentration is related to potential through the Nernst equation.

**PCO<sub>2</sub>**

PCO<sub>2</sub> is measured by direct potentiometry. In the calculation of results for PCO<sub>2</sub>, concentration is related to potential through the Nernst equation.

**Temperature “Correction” Algorithm**

pH, and PCO<sub>2</sub> are temperature-dependent quantities and are measured at 37 °C. The pH and PCO<sub>2</sub> readings at a body temperature other than 37 °C can be ‘corrected’ by entering the patient’s temperature on the chart page of the analyzer. In this case, blood gas results will be displayed at both 37°C and the patient’s temperature.

pH and PCO<sub>2</sub> at the patient’s temperature (T<sub>p</sub>) are calculated as follows<sup>3</sup>:

$$pH(T_p) = pH - 0.0147(T_p - 37) + 0.0065(7.4 - pH)(T_p - 37)$$

$$PCO_2(T_p) = PCO_2 \times 10^{0.019(T_p - 37)}$$

**Calculated:****Anion Gap (AnGap)**

Anion Gap is calculated in the EC8+ cartridge as follows:

$$\text{Anion Gap (EC8+)} = (\text{Na} + \text{K}) - (\text{Cl} + \text{HCO}_3)$$

Anion gap is reported as the difference between the commonly measured cations sodium and potassium and the commonly measured anions chloride and bicarbonate. The size of the gap reflects unmeasured cations and anions and is therefore an analytical gap. Physiologically, a deficit of anions cannot exist. While relatively nonspecific, anion gap is useful for the detection of organic acidosis due to an increase in anions that are difficult to measure. Anion gap can be used to classify metabolic acidosis into high and normal anion gap types.

**Hemoglobin (Hb)**

The i-STAT System provides a calculated hemoglobin result which is determined as follows:

$$\text{hemoglobin (g/dL)} = \text{hematocrit (\% PCV)} \times 0.34$$

$$\text{hemoglobin (g/dL)} = \text{hematocrit (decimal fraction)} \times 34$$

To convert a hemoglobin result from g/dL to mmol/L, multiply the displayed result by 0.621. The calculation of hemoglobin from hematocrit assumes a normal MCHC.

## HCO<sub>3</sub>, TCO<sub>2</sub>, and BE

- HCO<sub>3</sub> (bicarbonate), the most abundant buffer in the blood plasma, is an indicator of the buffering capacity of blood. Regulated primarily by the kidneys, HCO<sub>3</sub> is the metabolic component of acid-base balance.
- TCO<sub>2</sub> is a measure of carbon dioxide which exists in several states: CO<sub>2</sub> in physical solution or loosely bound to proteins, bicarbonate (HCO<sub>3</sub>) or carbonate (CO<sub>3</sub>) anions, and carbonic acid (H<sub>2</sub>CO<sub>3</sub>). Measurement of TCO<sub>2</sub> as part of an electrolyte profile is useful chiefly to evaluate HCO<sub>3</sub> concentration. TCO<sub>2</sub> and HCO<sub>3</sub> are useful in the assessment of acid-base imbalance (along with pH and **PCO<sub>2</sub>**) and electrolyte imbalance.
- The calculated TCO<sub>2</sub> provided by the i-STAT System is determined from the measured and reported values of pH and **PCO<sub>2</sub>** according to a simplified and standardized form of the Henderson-Hasselbalch equation.<sup>3</sup>
- This calculated TCO<sub>2</sub> measurement is metrologically traceable to the i-STAT pH and **PCO<sub>2</sub>** measurements, which are in turn traceable to primary standard reference materials for pH and **PCO<sub>2</sub>**. Like all calculated parameters reported by the i-STAT System, the user can independently determine TCO<sub>2</sub> values from the reported pH and **PCO<sub>2</sub>** measurements using a combination of the equation for HCO<sub>3</sub> given in the **PCO<sub>2</sub>**.
- Base excess of the extracellular fluid (ECF) or standard base excess is defined as the concentration of titratable base minus the concentration of titratable acid when titrating the average ECF (plasma plus interstitial fluid) to an arterial plasma pH of 7.40 at **PCO<sub>2</sub>** of 40 mmHg at 37 °C. Excess concentration of base in the average ECF remains virtually constant during acute changes in the **PCO<sub>2</sub>** and reflects only the non-respiratory component of pH-disturbances.

When a cartridge includes sensors for both pH and **PCO<sub>2</sub>**, bicarbonate (HCO<sub>3</sub>), total carbon dioxide (TCO<sub>2</sub>) and base excess (BE) are calculated.<sup>3</sup>

$$\log \text{HCO}_3 = \text{pH} + \log \text{PCO}_2 - 7.608$$

$$\text{TCO}_2 = \text{HCO}_3 + 0.03\text{PCO}_2$$

$$\text{BE}_{\text{ecf}} = \text{HCO}_3 - 24.8 + 16.2(\text{pH} - 7.4)$$

$$\text{BE}_b = (1 - 0.014 \cdot \text{Hb}) * [\text{HCO}_3 - 24.8 + (1.43 * \text{Hb} + 7.7) * (\text{pH} - 7.4)]$$

See below for information on factors affecting results. Certain substances, such as drugs, may affect analyte levels in vivo.<sup>4</sup> If results appear inconsistent with the clinical assessment, the patient sample should be retested using another cartridge.

## REAGENTS

### Contents

Each i-STAT cartridge contains one reference electrode sensor, sensors for the measurement of specific analytes, and a buffered aqueous calibrant solution that contains known concentrations of analytes and preservatives. A list of reactive ingredients for the EC8+ cartridge is shown below:

Sensor	Reactive Ingredient	Biological Source	Minimum Quantity
Na	Sodium (Na <sup>+</sup> )	N/A	121 mmol/L
K	Potassium (K <sup>+</sup> )	N/A	3.6 mmol/L
Cl	Chloride (Cl <sup>-</sup> )	N/A	91 mmol/L
Glu	Glucose	N/A	7 mmol/L
	Glucose Oxidase	<i>Aspergillus niger</i>	0.002 IU
BUN/Urea	Urea	N/A	4 mmol/L

Sensor	Reactive Ingredient	Biological Source	Minimum Quantity
	Urease	<i>Canavalia ensiformis</i>	0.12 IU
pH	Hydrogen Ion (H <sup>+</sup> )	N/A	6.66 pH
PCO <sub>2</sub>	Carbon Dioxide (CO <sub>2</sub> )	N/A	25.2 mmHg

### Warnings and Precautions

- For *in vitro* diagnostic use.
- DO NOT REUSE—cartridges are intended for single-use only.
- Refer to the i-STAT 1 System Manual for all warnings and precautions.

### Storage Conditions

- Refrigeration at 2–8 °C (35–46 °F) until expiration date.
- Room Temperature at 18–30 °C (64–86 °F). Refer to the cartridge box for recommended shelf life.

## INSTRUMENTS

The EC8+ cartridge is intended for use with the i-STAT 1 analyzer REF 04P75-01 (Model 300-G) and REF 03P75-06 (Model 300W).

## SPECIMEN COLLECTION AND PREPARATION FOR ANALYSIS

### Specimen Types

Arterial, venous or capillary whole blood.

Sample volume: 65 µL

### Blood Collection Options and Test Timing (time from collection to cartridge fill)

Analyte	Syringes	Test Timing	Evacuated Tubes	Test Timing	Capillary Tubes	Test Timing
pH PCO <sub>2</sub>	Without anticoagulant	3 minutes	Without anticoagulant	3 minutes	With balanced heparin anticoagulant or lithium heparin if labeled for the measurement of electrolytes	3 minutes
	With balanced heparin anticoagulant or lithium heparin anticoagulant (syringe must be filled per manufacturer's recommendation) <ul style="list-style-type: none"> <li>• Maintain anaerobic conditions.</li> <li>• Remix thoroughly before filling cartridge.</li> </ul>	10 minutes	With lithium heparin anticoagulant (tubes must be filled per manufacturer's recommendation) <ul style="list-style-type: none"> <li>• Maintain anaerobic conditions.</li> <li>• Remix thoroughly before filling cartridge.</li> </ul>	10 minutes		
Sodium Potassium Chloride Glucose BUN/Urea Hematocrit	Without anticoagulant	3 minutes	Without anticoagulant	3 minutes	With balanced heparin anticoagulant or lithium heparin or lithium heparin if	3 minutes
	With balanced heparin anticoagulant or lithium heparin	30 minutes	With lithium heparin anticoagulant	30 minutes		

Analyte	Syringes	Test Timing	Evacuated Tubes	Test Timing	Capillary Tubes	Test Timing
	anticoagulant (syringe must be filled per manufacturer's recommendation) <ul style="list-style-type: none"> <li>Remix thoroughly before filling cartridge.</li> </ul>		(tubes must be filled per manufacturer's recommendation) <ul style="list-style-type: none"> <li>Remix thoroughly before filling cartridge.</li> </ul>		labeled for the measurement of electrolytes	

## PROCEDURE FOR CARTRIDGE TESTING

Each cartridge is sealed in a foil pouch for protection during storage--do not use if pouch has been punctured.

- A cartridge should not be removed from its protective pouch until it is at room temperature (18-30 °C or 64-86 °F). For best results, the cartridge and analyzer should be at room temperature.
- Since condensation on a cold cartridge may prevent proper contact with the analyzer, allow refrigerated cartridges to equilibrate at room temperature for 5 minutes for a single cartridge and 1 hour for an entire box before use.
- Use a cartridge immediately after removing it from its protective pouch. Prolonged exposure may cause a cartridge to fail a Quality Check.
- Do not return unopened, previously refrigerated cartridges to the refrigerator.
- Cartridges may be stored at room temperature for the time frame indicated on the cartridge box.

**Filling and Sealing the Cartridge** (after cartridge has been equilibrated and blood sample has been collected)

1. Place the cartridge on a flat surface.
2. Mix the sample thoroughly. Invert a lithium heparin blood collection tube at least 10 times. If sample was collected into a syringe, invert syringe for 5 seconds then roll the syringe between the palms (hands parallel to the ground) for 5 seconds, flip and roll for an additional 5 seconds. The blood in the hub of the syringe will not mix, therefore expelling 2 drops before filling a cartridge is desired. Note that it may be difficult to properly mix a sample in a 1.0 mL syringe.
3. Fill the cartridge immediately after mixing. Direct the hub of syringe or tip of the transfer device (capillary tube, pipette, or dispensing tip) into the sample well of the cartridge.
4. Slowly dispense sample into the sample well until the sample reaches the fill mark indicated on the cartridge. Cartridge is properly filled when the sample reaches the 'fill to' mark and a small amount of sample is in the sample well. The sample should be continuous, no bubbles or breaks (see System Manual for details).
5. Fold the snap closure of the cartridge over the sample well.

## Performing Patient Analysis

1. Press the power button to turn on the handheld.
2. Press 2 for *i-STAT Cartridge*.
3. Follow the handheld prompts.
4. Scan the lot number on the cartridge pouch.
5. Continue normal procedures for preparing the sample, and filling and sealing the cartridge.
6. Push the sealed cartridge into the handheld port until it clicks into place. Wait for the test to complete.
7. Review the results.

For additional information for cartridge testing, refer to the i-STAT 1 System Manual located at [www.pointofcare.abbott](http://www.pointofcare.abbott).

### **Analysis Time**

Approximately 130–200 seconds.

### **Quality Control**

The i-STAT quality control regimen comprises four aspects, with a system design that reduces the opportunity for error, including:

1. A series of automated, on-line quality measurements that monitors the sensors, fluidics, and instrumentation each time a test is performed.
2. A series of automated, on-line procedural checks that monitors the user each time a test is performed.
3. Liquid materials are available to be used to verify the performance of a batch of cartridges when they are first received or when storage conditions are in question. The performance of this procedure is not a manufacturer's system instruction.
4. Traditional quality control measurements that verify the instrumentation using an independent device, which simulates the characteristics of the electrochemical sensors in a way that stresses the performance characteristics of the instrumentation.

For additional information on Quality Control, refer to the i-STAT 1 System Manual located at [www.pointofcare.abbott](http://www.pointofcare.abbott).

### **Calibration Verification**

Calibration Verification is a procedure intended to verify the accuracy of results over the entire measurement range of a test. The performance of this procedure is not a manufacturer's system instruction. However, it may be required by regulatory or accreditation bodies. While the Calibration Verification Set contains five levels, verification of the measurement range could be accomplished using the lowest, highest and mid-levels.



## EXPECTED VALUES

TEST	UNITS *	REPORTABLE RANGE	REFERENCE RANGE	
			arterial	venous
<b>MEASURED</b>				
Na	mmol/L (mEq/L)	100–180	138–146 <sup>5</sup>	
K	mmol/L (mEq/L)	2.0–9.0	3.5–4.9 <sup>5**</sup>	
Cl	mmol/L (mEq/L)	65–140	98–109 <sup>5</sup>	
Glu	mmol/L	1.1–38.9	3.9–5.8 <sup>6</sup>	
	mg/dL	20–700	70–105 <sup>6</sup>	
	g/L	0.20–7.00	0.70–1.05 <sup>6</sup>	
BUN/Urea Nitrogen	mg/dL	3–140	8–26 <sup>5</sup>	
Urea	mmol/L	1–50	2.9–9.4 <sup>5</sup>	
	mg/dL	6–300	17–56 <sup>5</sup>	
	g/L	0.06–3.00	0.17–0.56 <sup>5</sup>	
Hematocrit/Hct	% PCV ***	15–75	38–51 <sup>5****</sup>	
	Fraction	0.15–0.75	0.38–0.51 <sup>5</sup>	
pH		6.50 - 8.20	7.35 - 7.45 <sup>6</sup>	7.31 - 7.41 <sup>*****</sup>
PCO <sub>2</sub>	mmHg	5 - 130	35 - 45 <sup>6</sup>	41 - 51
	kPa	0.67 - 17.33	4.67 - 6.00	5.47 - 6.80
<b>CALCULATED</b>				
AnGap	mmol/L	(-10)–(+99)	10–20 <sup>6</sup>	
Hemoglobin/Hb	g/dL	5.1–25.5	12–17 <sup>5****</sup>	
	g/L	51–255	120–170 <sup>5</sup>	
	mmol/L	3.2–15.8	7–11.5	
Bicarbonate/ HCO <sub>3</sub>	mmol/L (mEq/L)	1.0 - 85.0	22 - 26 <sup>*****</sup>	23 - 28 <sup>*****</sup>
TCO <sub>2</sub>	mmol/L (mEq/L)	5 - 50	23 - 27	24 - 29
Base Excess/ BE	mmol/L (mEq/L)	(-30) – (+30)	(-2) – (+3) <sup>6</sup>	(-2) – (+3) <sup>6</sup>

\* The i-STAT System can be configured with the preferred units. Not applicable for pH test.

\*\* The reference range for potassium has been reduced by 0.2 mmol/L from the range cited in Reference 5 to account for the difference in results between serum and plasma.

\*\*\* PCV, packed cell volume.

\*\*\*\* The reference ranges for hematocrit and hemoglobin span both female and male populations.

\*\*\*\*\* Calculated from Siggard-Andersen nomogram.<sup>1</sup>

### Unit Conversion

- **Glucose (Glu):** To convert mg/dL to mmol/L, multiply the mg/dL value by 0.055.
- **BUN/Urea:** To convert a BUN result in mg/dL to a urea result in mmol/L, multiply the BUN result by 0.357. To convert a urea result in mmol/L to a urea result in mg/dL, multiply the mmol/L result by 6. To convert a urea result in mg/dL to a urea result in g/L, divide the mg/dL result by 100.
- **Hematocrit (Hct):** To convert a result from % PCV (packed cell volume) to fraction packed cell

volume, divide the % PCV result by 100. For the measurement of hematocrit, the i-STAT System can be customized to agree with methods calibrated by the microhematocrit reference method using either K<sub>3</sub>EDTA or K<sub>2</sub>EDTA anticoagulant. Mean cell volumes of K<sub>3</sub>EDTA anticoagulated blood are approximately 2–4% less than K<sub>2</sub>EDTA anticoagulated blood. While the choice of anticoagulant affects the microhematocrit method to which all hematocrit methods are calibrated, results from routine samples on hematology analyzers are independent of the anticoagulant used. Since most clinical hematology analyzers are calibrated by the microhematocrit method using K<sub>3</sub>EDTA anticoagulant, the i-STAT System default customization is K<sub>3</sub>EDTA.

- **PCO<sub>2</sub>:** To convert **PCO<sub>2</sub>** results from mmHg to kPa, multiple the mmHg value by 0.133.

The reference ranges programmed into the analyzer and shown above are intended to be used as guides for the interpretation of results. Since reference ranges may vary with demographic factors such as age, gender and heritage, it is recommended that reference ranges be determined for the population being tested.

## METROLOGICAL TRACEABILITY

The measured analytes in the i-STAT EC8+ cartridge are traceable to the following reference materials or methods. The i-STAT System controls and calibration verification materials are validated for use only with the i-STAT System and assigned values may not be commutable with other methods.

### **Sodium (Na), Potassium (K) and Chloride (Cl)**

The respective analyte values assigned to i-STAT System controls and calibration verification materials are traceable to the U.S. National Institute of Standards and Technology (NIST) standard reference material SRM956.

### **Glucose (Glu)**

The i-STAT System test for glucose measures glucose amount-of-substance concentration in the plasma fraction of arterial, venous, or capillary whole blood (dimension mmol L<sup>-1</sup>) for *in vitro* diagnostic use. Glucose values assigned to i-STAT System controls and calibration verification materials are traceable to the U.S. National Institute of Standards and Technology (NIST) standard reference material SRM965. i-STAT System controls and calibration verification materials are validated for use only with the i-STAT System and assigned values may not be commutable with other methods.

### **Blood Urea Nitrogen (BUN/Urea)**

The i-STAT System test for blood urea nitrogen/urea measures blood urea nitrogen/urea amount-of-substance concentration in the plasma fraction of arterial, venous, or capillary whole blood (dimension mmol L<sup>-1</sup>) for *in vitro* diagnostic use. BUN/urea values assigned to i-STAT System controls and calibration verification materials are traceable to the U.S. National Institute of Standards and Technology (NIST) standard reference material SRM909. i-STAT System controls and calibration verification materials are validated for use only with the i-STAT System and assigned values may not be commutable with other methods.

### **Hematocrit (Hct)**

The i-STAT System test for hematocrit measures packed red blood cell volume fraction in arterial, venous, or capillary whole blood (expressed as the % packed cell volume) for *in vitro* diagnostic use. Hematocrit values assigned to i-STAT working calibrators are traceable to the Clinical and Laboratory Standards Institute (CLSI) H7-A3 procedure for determining packed cell volume by the microhematocrit method. 7

### **pH**

The i-STAT System test for pH measures the hydrogen ion amount-of-substance concentration in the plasma fraction of arterial, venous, or capillary whole blood (expressed as the negative logarithm of the relative molal hydrogen ion activity) for *in vitro* diagnostic use. pH values assigned to i-STAT System

controls and calibration verification materials are traceable to the U.S. National Institute of Standards and Technology (NIST) standard reference materials SRMs 186-I, 186-II, 185, and 187.

### **PCO<sub>2</sub>**

The i-STAT System test for carbon dioxide partial pressure measures carbon dioxide partial pressure in arterial, venous, or capillary whole blood (dimension kPa) for *in vitro* diagnostic use. PCO<sub>2</sub> values assigned to i-STAT System controls and calibration verification materials are traceable to U.S. National Institute of Standards and Technology (NIST) standard reference materials via commercially available certified specialty medical gas standards.

Additional information regarding metrological traceability is available from Abbott Point of Care Inc.

## **PERFORMANCE CHARACTERISTICS**

The typical performance data summarized below were collected in health care facilities by health care professionals trained in the use of the i-STAT System and comparative methods.

### **Precision**

Precision data collected was collected in multiple sites and tested as follows: Duplicates of each control fluid were tested in the morning and in the afternoon on five days for a total of 20 replicates. The averaged statistics are presented below.

<b>Test</b>	<b>Units</b>	<b>Aqueous Control</b>	<b>Mean</b>	<b>SD (Standard Deviation)</b>	<b>CV (%) [Coefficient of Variation (%)]</b>
Na	mmol/L or mEq/L	Level 1	120.0	0.46	0.4
		Level 3	160.0	0.53	0.3
K	mmol/L or mEq/L	Level 1	2.85	0.038	1.3
		Level 3	6.30	0.039	0.6
Cl	mmol/L or mEq/L	Level 1	76.7	0.54	0.7
		Level 3	114.0	0.56	0.5
Glu	mg/dL	Level 1	41.8	0.68	1.6
		Level 3	289	2.4	0.8
BUN/Urea	mg/dL	Level 1	52.8	0.76	1.4
		Level 3	5.5	0.45	8.2
Hct	% PCV (packed cell volume)	Low	30.0	0.44	1.5
		High	49.0	0.50	1.0
pH		Level 1	7.165	0.005	0.08
		Level 3	7.656	0.003	0.04
PCO <sub>2</sub>	mmHg	Level 1	63.8	1.57	2.5
		Level 3	19.6	0.40	2.0

### **Method Comparison**

Method comparison data were collected using CLSI guideline EP9-A.<sup>8</sup>

Deming regression analysis<sup>9</sup> was performed on the first replicate of each sample set. In the method comparison table, n is the number of specimens in the data set, Sxx and Syy refer to estimates of imprecision based on the duplicates of the comparative and the i-STAT methods respectively, Sy.x is the standard error of the estimate, and r is the correlation coefficient.\*

Method comparisons will vary from site to site due to differences in sample handling, comparative method calibration and other site-specific variables.

\* The usual warning relating to the use of regression analysis is summarized here as a reminder. For any analyte, “if the data is collected over a narrow range, the estimate of the regression parameters are relatively imprecise and may be biased. Therefore, predictions made from these estimates may be invalid”.<sup>9</sup> The correlation coefficient, r, can be used as a guide to assess the adequacy of the comparative method range in overcoming this problem, and, as a guide, the range of data can be considered adequate for  $r > 0.975$ .

<b>Sodium/Na (mmol/L or mEq/L)</b>		<b>Beckman Synchron CX<sup>®</sup>3</b>	<b>Kodak Ektachem<sup>™</sup> 700</b>	<b>Nova STAT Profile<sup>®</sup> 5</b>
Venous blood samples were collected in lithium heparin Vacutainer <sup>®</sup> tubes and analyzed in duplicate on the i-STAT System. A portion of the specimen was centrifuged and the separated plasma was analyzed in duplicate on comparative methods within 20 minutes of collection.	n	189	142	192
	Sxx	0.74	0.52	0.54
	Syy	0.53	0.58	0.53
	Slope	1.00	0.98	0.95
	Int't	-0.11	3.57	5.26
	Sy.x	1.17	1.04	1.53
	Xmin	126	120	124
	Xmax	148	148	148
	r	0.865	0.937	0.838
<b>Potassium/K (mmol/L or mEq/L)</b>		<b>Beckman Synchron CX<sup>®</sup>3</b>	<b>Kodak Ektachem<sup>™</sup> 700</b>	<b>Nova STAT Profile<sup>®</sup> 5</b>
Venous blood samples were collected in lithium heparin Vacutainer <sup>®</sup> tubes and analyzed in duplicate on the i-STAT System. A portion of the specimen was centrifuged and the separated plasma was analyzed in duplicate on comparative methods within 20 minutes of collection.	n	189	142	192
	Sxx	0.060	0.031	0.065
	Syy	0.055	0.059	0.055
	Slope	0.97	1.06	0.99
	Int't	0.02	-0.15	-0.01
	Sy.x	0.076	0.060	0.112
	Xmin	2.8	3.0	2.8
	Xmax	5.7	9.2	5.8
	r	0.978	0.993	0.948
<b>Chloride/Cl (mmol/L or mEq/L)</b>		<b>Beckman Synchron CX<sup>®</sup>3</b>	<b>Kodak Ektachem<sup>™</sup> 700</b>	<b>Nova STAT Profile<sup>®</sup> 5</b>
Venous blood samples were collected in lithium heparin Vacutainer <sup>®</sup> tubes and analyzed in duplicate on the i-STAT System. A portion of the specimen was centrifuged and the separated plasma was analyzed in duplicate on comparative methods within 20 minutes of collection.	n	189	142	192
	Sxx	1.27	0.41	0.89
	Syy	0.88	0.90	0.88
	Slope	0.99	0.88	0.93
	Int't	-0.82	14.6	4.3
	Sy.x	1.65	1.84	2.33
	Xmin	93	63	96
	Xmax	114	128	117
	r	0.817	0.914	0.752
<b>Glucose/Glu (mg/dL)</b>		<b>Beckman Coulter LX20<sup>®</sup></b>	<b>Bayer 860</b>	<b>Dade Dimension RxL-Xpand</b>
Venous blood samples were collected in lithium heparin Vacutainer <sup>®</sup> tubes and analyzed in duplicate on the i-STAT System. A portion of the specimen was centrifuged and the separated plasma was analyzed in duplicate on	n	35	40	32
	Sxx	2.21	4.71	0.98
	Syy	0.69	0.96	0.59
	Slope	1.03	0.99	1.01
	Int't	-3.39	-1.67	-0.85
	Sy.x	0.91	0.70	1.57

comparative methods within 20 minutes of collection.	Xmin	45	58	48	
	Xmax	297	167	257	
	r	0.999	0.993	0.998	
<b>BUN/Urea (mg/dL)</b>		<b>Beckman Coulter LX20®</b>	<b>Dade Dimension RxL-Xpand®</b>	<b>Beckman Coulter CX9®</b>	
Venous blood samples were collected in lithium heparin Vacutainer® tubes and analyzed in duplicate on the i-STAT System.  A portion of the specimen was centrifuged and the separated plasma was analyzed in duplicate on comparative methods within 20 minutes of collection.	n	39	32	26	
	Sxx	0.36	0.48	0.39	
	Syy	0.67	0.34	0.60	
	Slope	1.03	1.05	1.00	
	Int't	1.39	-0.28	-0.38	
	Sy.x	0.99	0.31	0.85	
	Xmin	5	5	7	
	Xmax	70	38	66	
	r	0.997	0.998	0.997	
<b>Hematocrit/Hct (% PCV) (% packed cell volume)</b>		<b>Coulter® S Plus</b>	<b>Nova STAT Profile® 5</b>	<b>Abbott Cell-Dyn 4000</b>	<b>Sysmex SE9500</b>
Venous blood samples, collected in lithium heparin Vacutainer® tubes, were analyzed in duplicate on the i-STAT System and on the comparative methods for hematocrit within 20 minutes of collection.	n	142	192	29	29
	Sxx	0.50	0.46	0.41	0.53
	Syy	1.09	1.31	0.77	0.76
	Slope	0.98	1.06	1.06	1.11
	Int't	1.78	-3.98	-1.42	-4.19
	Sy.x	2.03	2.063	1.13	0.98
	Xmin	18	21	19	24
	Xmax	51	50	46	47
	r	0.952	0.932	0.993	0.980
<b>pH</b>		<b>IL BGE</b>	<b>Radiometer ICA 1</b>	<b>Nova STAT Profile 5</b>	<b>Radiometer ABL500</b>
Venous blood samples were collected in evacuated tubes and arterial samples were collected in blood gas syringes with lithium heparin anticoagulant.  All sample were analyzed in duplicate on the i-STAT System and on the comparative methods within 10 minutes of each other. Arterial blood samples were collected from hospital patients in 3 mL blood gas syringes and were analyzed in duplicate on the i-STAT System and the comparative method within 5 minutes of each other.	n	62	47	57	45
	Sxx	0.005	0.011	0.006	0.004
	Syy	0.009	0.008	0.008	0.008
	Slope	0.974	1.065	1.058	1.0265
	Int't	0.196	-0.492	-0.436	-0.1857
	Sy.x	0.012	0.008	0.010	0.0136
	Xmin	7.210	7.050	7.050	----
	Xmax	7.530	7.570	7.570	----
	r	0.985	0.990	0.9920	0.986
<b>Carbon Dioxide Partial Pressure/PCO<sub>2</sub> (mmHg)</b>		<b>IL BGE</b>	<b>Radiometer ABL500</b>		
Venous blood samples were collected in blood gas syringes.  All samples were analyzed in duplicate on the i-STAT System and on the comparative methods within 10 minutes of each other. Arterial blood samples were collected from hospital patients in 3 cc blood gas syringes and were analyzed in	n	62	29		
	Sxx	0.69	0.74		
	Syy	1.24	0.53		
	Slope	1.003	1.016		
	Int't	-0.8	1.1		
	Sy.x	1.65	0.32		
	Xmin	30.4	28		

duplicate on the i-STAT System and the comparative method within 5 minutes of each other.	Xmax	99.0	91
	r	0.989	0.999

## FACTORS AFFECTING RESULTS

The following substances were evaluated in plasma for relevant analytes at the test concentrations recommended in CLSI guideline EP7-A2<sup>10</sup> unless otherwise noted. For those identified as an interferant the interference is described.

Substance	Test Concentration (mmol/L)	Analyte	Interference (Yes/No)	Comment
Acetaldehyde	0.045 <sup>11</sup>	Glu	No	
Acetaminophen	1.32	Na	No	
		K	No	
		Cl	No	
		Glu	Yes	Increased results
		BUN	No	
Acetaminophen (therapeutic)	0.132 <sup>11</sup>	Glu	No	
Acetoacetate	2.0	Glu	No	
Acetylcysteine	10.2	Na	No	
		K	No	
		Cl	Yes	Increased results
		Glu	Yes	Decreased results
		BUN	No	
Acetylcysteine (therapeutic)	0.30 <sup>12 13</sup>	Cl	No	
Ascorbate	0.34	Glu	No	
		Na	No	
		K	No	
		Cl	No	
		Glu	No	
Bromide	37.5	BUN	No	
		Na	Yes	Increased results. Use another method.
		K	Yes	Increased results and rate of star (***) outs. Use another method.
		Cl	Yes	Increased results. Use another method.
		Glu	Yes	Decreased results. Use another method.
		BUN	Yes	Decreased result and increased rate of star (***) outs. Use another method.
Bromide (therapeutic)	2.5 <sup>14 15 16</sup>	Hct	Yes	Increased rate of star (***) outs
		Na	No	
		K	No	
		Cl	Yes	Increased results. Use another method.
		Glu	Yes	Decreased results
		BUN	No	
		Hct	No	
Dopamine	0.006	Glu	No	
Formaldehyde	0.133 <sup>11</sup>	Glu	No	

Substance	Test Concentration (mmol/L)	Analyte	Interference (Yes/No)	Comment
β-Hydroxybutyrate	6.0 <sup>17</sup>	Na	No	
		K	No	
		Cl	No	
		Glu	No	
		BUN	No	
Hydroxyurea	0.92	Glu	Yes	Increased results. Use another method.
		BUN	Yes	Increased results
Iodide	2.99	Cl	Yes	Increased results
	0.4	Cl	No	
Lactate	6.6	Na	No	
		K	No	
		Cl	No	
		Glu	No	
		BUN	No	
Magnesium Chloride	1.0	Na	No	
		K	No	
Maltose	13.3	Glu	No	
Nithiodote (Sodium thiosulfate)	16.7 <sup>18</sup>	Na	Yes	Increased results
		K	Yes	Decreased results
		Cl	Yes	Increased results
		Glu	Yes	Decreased results
		BUN	Yes	Decreased results
Pyruvate	0.31	Glu	No	
Salicylate	4.34	Na	No	
		K	No	
		Cl	Yes	Increased results. Use another method.
		Glu	No	
		BUN	No	
Salicylate (therapeutic)	0.5 <sup>19</sup>	Cl	No	
Thiocyanate	6.9	Cl	Yes	Increased results. Use another method
		Glu	Yes	Decreased results
		BUN	No	
Thiocyanate (therapeutic)	0.5 <sup>11</sup>	Glu	No	
Uric Acid	1.4	Glu	No	

The degree of interference at concentrations other than those reported above might not be predictable. It is possible that interfering substances other than those tested may be encountered.

Relevant comments regarding interference of Acetaminophen, Acetylcysteine, Bromide, Hydroxyurea, Iodide, Nithiodote and Salicylate are noted below:

- Acetaminophen has been shown to interfere with i-STAT glucose results at a concentration proscribed by the CLSI guideline, 1.32 mmol/L, which represents a toxic concentration. Acetaminophen at 0.132 mmol/L, which represents the upper end of the therapeutic concentration, has been shown not to significantly interfere with i-STAT glucose results.
- Acetylcysteine has been tested at two levels: the CLSI recommended level of 10.2 mmol/L and a concentration of 0.30 mmol/L. The latter is 3 times the peak therapeutic plasma concentration

associated with treatment to reverse acetaminophen poisoning. APOC has not identified a therapeutic condition that would lead to levels consistent with the CLSI recommended level.

- Bromide has been tested at two levels: the CLSI recommended level and a therapeutic plasma concentration level of 2.5 mmol/L. The latter is the peak plasma concentration associated with halothane anesthesia, in which bromide is released. APOC has not identified a therapeutic condition that would lead to levels consistent with the CLSI recommended level.
- Hydroxyurea has been shown to interfere with glucose and BUN results at 0.92 mmol/L. Hydroxyurea is a DNA synthesis inhibitor used in the treatment sickle cell anemia, HIV infection, and various types of cancer. The malignancies that it is used to treat include melanoma, metastatic ovarian cancer, and chronic myelogenous leukemia. It is also used in the treatment of polycythemia vera, thrombocytopenia, and psoriasis. At typical doses ranging from 500 mg to 2 g/day, concentrations of hydroxyurea in a patient's blood may be sustained at approximately 100 to 500 µmol/L. Higher concentrations may be observed soon after dosing or at higher therapeutic doses.
- Iodide has been tested at the CLSI recommended level of 2.99 mmol/L, which is close to the peak concentration after a lethal dose. A lethal dose is reported to be in the range of 2–4 grams<sup>20</sup>, which equates to 3.1–6.3 mmol/L assuming the dose is fully distributed in a typical blood volume of 5 L. Iodide can be used to treat thyroid disease (i.e., hyperthyroidism). A study showed serum iodide reaches mean peak concentration between 1.8 mg/L (0.014 mmol/L) and 2.2 mg/L (0.017 mmol/L) after a month of supplementation at 50 mg/day.<sup>21</sup> Iodide has been shown to interfere with i-STAT chloride results at 2.99 mmol/L. The lowest concentration tested at APOC of 0.4 mmol/L has been shown to not significantly interfere with i-STAT chloride results. APOC has not identified a therapeutic condition that would lead to levels consistent with the CLSI recommended level.
- Nithiodote (sodium thiosulfate) has been shown to interfere with sodium, potassium, chloride, glucose and BUN results at 16.7 mmol/L. Nithiodote (sodium thiosulfate) is indicated for the treatment of acute cyanide poisoning. The journal article titled "Falsely increased chloride and missed anion gap elevation during treatment with sodium thiosulfate" indicated that sodium thiosulfate could be used in the treatment of calciphylaxis indicating that "the highest concentration likely to be seen in plasma [is] after infusion of a 12.5 g dose of sodium thiosulfate pentahydrate. Assuming that the 12.5 g dose of sodium thiosulfate pentahydrate is distributed in a typical blood volume of 5 L with a hematocrit of 40%, the peak sodium thiosulfate plasma concentration expected is 16.7 mmol/L."<sup>18</sup>
- Salicylate has been shown to interfere with i-STAT chloride result at 4.34 mmol/L, a toxic concentration that is proscribed by the CLSI guideline. Salicylate at 0.5 mmol/L, which represents the upper end of the therapeutic concentration range, has been shown not to significantly interfere with i-STAT chloride results.

## OTHER FACTORS AFFECTING RESULTS

Factor	Analyte	Effect
Sodium heparin	Na	Sodium heparin may increase sodium results up to 1 mmol/L. <sup>22</sup>
Exposing the sample to air	pH	Exposing the sample to air allows CO <sub>2</sub> to escape which causes PCO <sub>2</sub> to decrease and pH to increase and HCO <sub>3</sub> and TCO <sub>2</sub> to be underestimated.
	PCO <sub>2</sub>	
	HCO <sub>3</sub>	
	TCO <sub>2</sub>	
Venous stasis	pH	Venous stasis (prolonged tourniquet application) and forearm exercise may decrease pH due to localized production of lactic acid.
Line draw	Hct	Low hematocrit results can be caused by contamination of flush solutions in arterial or venous lines. Back flush a line with a sufficient amount of blood to remove intravenous solutions, heparin, or medications that may contaminate the sample. Five to six times the volume of the catheter, connectors, and needle is recommended.
Hemodilution	Na	Hemodilution of the plasma by more than 20% associated with priming cardiopulmonary bypass pumps, plasma volume expansion or other fluid administration therapies using certain solutions may cause
	Cl	
	pH	










Factor	Analyte	Effect
		clinically significant error on sodium, chloride, ionized calcium and pH results. These errors are associated with solutions that do not match the ionic characteristics of plasma. To minimize these errors when hemodiluting by more than 20%, use physiologically balanced multi-electrolyte solutions containing low-mobility anions (e.g., gluconate).
Cold temperature	K	Potassium values will increase in iced specimens.
Allowing blood to stand (without exposure to air)	K	If heparinized whole blood is allowed to stand before testing, potassium values will first decrease slightly, then increase over time.
	Glu	Glucose values will decrease in whole blood samples over time. Venous blood glucose is as much as 7 mg/dL less than capillary blood glucose as a result of tissue utilization. <sup>23</sup>
	pH	pH decreases on standing anaerobically at room temperature at a rate of 0.03 pH units per hour. <sup>1</sup>
	PCO <sub>2</sub>	Standing anaerobically at room temperature will increase PCO <sub>2</sub> by approximately 4 mmHg per hour.
	HCO <sub>3</sub> TCO <sub>2</sub>	Allowing blood to stand (without exposure to air) before testing allows PCO <sub>2</sub> to increase and pH to decrease, which will cause HCO <sub>3</sub> and TCO <sub>2</sub> to be over-estimated, due to metabolic processes.
Sample type	K	Serum Potassium results may be 0.1 to 0.7 mmol/L higher than Potassium results from anticoagulated samples due to the release of Potassium from platelets <sup>2</sup> and red blood cells during the clotting process.
Sample mixing	Hct	Samples from 1 mL syringes should not be used to determine hematocrit if testing is delayed.
Hemolysis	K	Potassium values obtained from skin puncture samples may vary due to hemolysis or an increase in tissue fluid from improper technique during the collection procedure.
Under fill or partial draw	PCO <sub>2</sub>	The use of partial draw tubes (evacuated tubes that are adjusted to draw less than the tube volume, e.g., a 5 mL tube with enough vacuum to draw only 3 mL) is not recommended due to the potential for decreased PCO <sub>2</sub> , HCO <sub>3</sub> and TCO <sub>2</sub> values. Underfilling blood collection tubes may also cause decreased PCO <sub>2</sub> , HCO <sub>3</sub> and TCO <sub>2</sub> results. Care must be taken to eliminate “bubbling” of the sample with a pipette when filling a cartridge to avoid the loss of CO <sub>2</sub> in the blood.
	HCO <sub>3</sub>	
	TCO <sub>2</sub>	
pH dependence	Glu	The dependence of the i-STAT glucose test with respect to pH is as follows: values below pH 7.4 at 37 °C decrease results by approximately 0.9 mg/dL (0.05 mmol/L) per 0.1 pH unit. Values above pH 7.4 at 37 °C increase results by approximately 0.8 mg/dL (0.04 mmol/L) per 0.1 pH unit.
PO <sub>2</sub> dependence	Glu	The dependence of the i-STAT glucose test with respect to PO <sub>2</sub> is as follows: oxygen levels of less than 20 mmHg (2.66 kPa) at 37 °C may decrease results.
Erythrocyte sedimentation rate	Hct	<ul style="list-style-type: none"> <li>The measurement of certain blood samples with high erythrocyte sedimentation rates (ESR) may be affected by analyzer angle. While testing blood samples, beginning 90 seconds after the cartridge is inserted, the analyzer should remain level until a result is obtained. A level surface includes running the handheld in the downloader/ recharger.</li> <li>Hematocrit results can be affected by the settling of red blood cells in the collection device. The best way to avoid the effect of settling is to test the sample immediately. If there is a delay in testing of a minute or more, the sample must be remixed thoroughly.</li> </ul>
White Blood Cell	Hct	Grossly elevated white blood cell counts may increase results.

Factor	Analyte	Effect							
Count (WBC)									
Lipids	Hct	Abnormally high lipids may increase results. Interference from lipids will be about two thirds the size of the interference from protein.							
Total Protein	Hct	Hematocrit results are affected by the level of total protein as follows:							
		<table border="1"> <thead> <tr> <th>Displayed Result</th> <th>Total Protein (TP) &lt; 6.5 g/dL</th> <th>Total Protein (TP) &gt; 8.0 g/dL</th> </tr> </thead> <tbody> <tr> <td>HCT &lt; 40% PCV</td> <td>Hct decreased by ~1% PCV for each decrease of 1 g/dL TP</td> <td>Hct increased by ~1% PCV for each increase of 1 g/dL TP</td> </tr> <tr> <td>HCT &gt; 40% PCV</td> <td>Hct decreased by ~0.75% PCV for each decrease of 1 g/dL TP</td> <td>Hct increased by ~0.75% PCV for each increase of 1 g/dL TP</td> </tr> </tbody> </table> <ul style="list-style-type: none"> <li>Total protein levels may be low in neonatal and burn patient populations, as well as in additional clinical populations listed in Statland.<sup>5</sup> Total protein levels may also be decreased in patients undergoing cardiopulmonary bypass (CPB) or extracorporeal membrane oxygenation (ECMO) and with patients receiving large volumes of saline-based intravenous (IV) fluids. Care should be taken when using hematocrit results from patients with total protein levels below the adult reference range (6.5 to 8 g/dL).</li> <li>The CPB sample type can be used to correct the hematocrit result for the dilutional effect of the pump prime in cardiovascular surgery. The CPB algorithm assumes that cells and plasma are diluted equally and that the pump priming solution has no added albumin or other colloid or packed red blood cells. Since perfusion practices vary, it is recommended that each practice verify the use of the CPB sample type and the length of time in which the CPB sample type should be used during the recovery period. Note that for hematocrit values above 30% PCV, the CPB correction is ≤1.5% PCV; the size of the correction at this level should not impact transfusion decisions.</li> </ul>	Displayed Result	Total Protein (TP) < 6.5 g/dL	Total Protein (TP) > 8.0 g/dL	HCT < 40% PCV	Hct decreased by ~1% PCV for each decrease of 1 g/dL TP	Hct increased by ~1% PCV for each increase of 1 g/dL TP	HCT > 40% PCV
Displayed Result	Total Protein (TP) < 6.5 g/dL	Total Protein (TP) > 8.0 g/dL							
HCT < 40% PCV	Hct decreased by ~1% PCV for each decrease of 1 g/dL TP	Hct increased by ~1% PCV for each increase of 1 g/dL TP							
HCT > 40% PCV	Hct decreased by ~0.75% PCV for each decrease of 1 g/dL TP	Hct increased by ~0.75% PCV for each increase of 1 g/dL TP							
Sodium	Hct	The sample electrolyte concentration is used to correct the measured conductivity prior to reporting hematocrit results. Factors that affect sodium will therefore also affect hematocrit.							
Clinical Conditions	Anion Gap	Anion gap may be only slightly increased in diarrhea and renal failure, but elevated (often >25) due to an increase in organic anions in lactic acidosis, ketoacidosis (alcoholic, diabetic, starvation) and uremia, an increase in inorganic anions in uremia, and an increase in anions from drugs such as salicylate and carbenicillin or toxins such as methanol and ethanol.							
	HCO <sub>3</sub>	Causes of primary metabolic acidosis (decrease calculated HCO <sub>3</sub> ) are ketoacidosis, lactate acidosis (hypoxia), and diarrhea. Causes of primary metabolic alkalosis (increase calculated HCO <sub>3</sub> ) are vomiting and antacid treatment.							
Propofol (Diprivan®) or thiopental sodium	PCO <sub>2</sub>	The use of EC8+ cartridges is not recommended for patients administered propofol (Diprivan®) or thiopental sodium (syn. thionembumal sodium, penthiobarbital sodium, thiopentone sodium, thionembutal, Pentothal Sodium®, Nesdonal Sodium®, IntraVal Sodium®, Trapanal®, and Thiothal Sodium <sup>24</sup> ).							
PO <sub>2</sub> sensitivity	PCO <sub>2</sub>	In patient samples where the PO <sub>2</sub> is > 100 mmHg above the normal range (80-105 mmHg), an increase in PCO <sub>2</sub> of approximately 1.5 mmHg (with a range of 0.9 to 2.0 mmHg) may be observed for every 100 mmHg increase in PO <sub>2</sub> .							

Factor	Analyte	Effect
		For example, if an oxygenated patient has a measured $PO_2$ of 200 mmHg, and a normal $PO_2$ is 100 mmHg, the impact to the $PCO_2$ result may be increased by approximately 1.5 mmHg.

For BUN/Urea, endogenous ammonium ions will not affect results.

## KEY TO SYMBOLS

Symbol	Definition/Use
<b>14</b> 	14 days room temperature storage at 18–30 °C.
	Use by or expiration date. The expiration date, expressed as YYYY-MM-DD, indicates the last day the product may be used.
<b>LOT</b>	Manufacturer's lot number or batch code. The lot number or batch code appears adjacent to this symbol.
	Sufficient for <n> tests.
<b>EC</b> <b>REP</b>	Authorized representative for Regulatory Affairs in the European Community.
	Temperature limitations. The upper and lower limits for storage are adjacent to upper and lower arms.
<b>REF</b>	Catalog number, list number, or reference.
	Do not reuse.
	Manufacturer.
	Consult instructions for use or see System Manual for instructions.
<b>IVD</b>	<i>In vitro</i> diagnostic medical device.
<b>CE</b>	Compliance to the European directive on <i>in vitro</i> diagnostic devices (98/79/EC)
<b>Rx ONLY</b>	For prescription use only.

**Additional Information:** to obtain additional product information and technical support, refer to the Abbott company website at [www.pointofcare.abbott](http://www.pointofcare.abbott).

## References

1. Pruden EL, Siggard-Andersen O, Tietz NW. Blood Gases and pH. In: C.A. Burtis and E.R. Ashwood, ed. *Tietz Textbook of Clinical Chemistry*. Second Edition ed. Philadelphia: W.B. Saunders Company; 1994.
2. Tietz NW, Pruden EL, Siggard-Andersen O. Electrolytes. In: C.A. Burtis and E.R. Ashwood, ed. *Tietz Textbook of Clinical Chemistry*. Second Edition ed. Philadelphia: W.B. Saunders Company; 1994.
3. CLSI. *Blood Gas and pH Analysis and Related Measurements; Approved Guideline*. Wayne, Pennsylvania; 2001.
4. Young DS. *Effects of Drugs on Clinical Laboratory Tests*. 3rd ed. ed. Washington, DC: American Association of Clinical Chemistry; 1990.
5. Statland BE. *Clinical Decision Levels for Lab Tests*. Oradell, NJ: Medical Economic Books; 1987.
6. Painter PC, Cope JY, Smith JL. Reference Ranges, Table 41–20. In: C.A. Burtis and E.R. Ashwood, ed. *Tietz Textbook of Clinical Chemistry*. Second Edition ed. Philadelphia: W.B. Saunders Company; 1994.
7. CLSI. *Procedure for Determining Packed Cell Volume by the Microhematocrit Method; Approved Standard-Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2000.
8. CLSI. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline. *CLSI document EP9-A*. 1995.
9. Cornbleet PJ, Gochman N. Incorrect least-squares regression coefficients in method-comparison analysis. *Clinical Chemistry*. 1979;25(3).
10. Clinical and Laboratory Standards Institute. Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition. *CLSI document EP7-A2*. 2005.
11. Wu AHB. *Tietz Clinical Guide to Laboratory Tests*: Elsevier Health Sciences; 2006.
12. Whillier S, Raftos JE, Chapman B, Kuchel PW. Role of N-acetylcysteine and cystine in glutathione synthesis in human erythrocytes. *Redox Report*. 2009;14(3):115-121.
13. Ventura P, Panini R, Pasini MC, Scarpetta G, Salvioli G. N-acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion. *Pharmacological Research*. 1999;40(4):345-350.
14. Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis. *Lancet*. May 1996;347(9012):1367-1371.
15. Morrison JE, Friesen RH. Elevated serum bromide concentrations following repeated halothane anaesthesia in a child. *Canadian Journal of Anaesthesia*. October 1990;37(7):801-803.
16. Hankins DC, Kharasch ED. Determination of the halothane metabolites trifluoroacetic acid and bromide in plasma and urine by ion chromatography. *Journal of Chromatography B: Biomedical Applications*. May 1997;692(2):413-418.
17. Charles RA, Bee YM, Eng PHK, Goh SY. Point-of-care blood ketone testing: Screening for diabetic ketoacidosis at the emergency department. *Singapore Medical Journal*. November 2007;48(11):986-989.

18. Wendroth SM, Heady TN, Haverstick DM, et al. Falsely increased chloride and missed anion gap elevation during treatment with sodium thiosulfate. *Clinica Chimica Acta*. April 2014;431:77-79.
19. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. *FASEB Journal*. October 2006;20(12):2009-2016.
20. Gosselin RE, Smith RP, Hodge HC. *Clinical Toxicology of Commercial Products*. Baltimore: Williams and Wilkins; 1984.
21. Abraham GE. Serum inorganic iodide levels following ingestion of a tablet form of Lugol solution: Evidence for an enterohepatic circulation of iodine. *The Original Internist*. 2005;11(3):112-118.
22. Tips on Specimen Collection. In: Mark Zacharia, ed. *Vol 1. Monograph of Medical Laboratory Observer's "Tips from the Clinical Experts"*. Montvale NJ: Medical Economics in collaboration with Becton, Dickinson and Company; 1997.
23. Young DS, Bermes EW. Influence of Site Collection on Blood Gases and pH. In: C.A. Burtis and E.R. Ashwood, ed. *Tietz Textbook of Clinical Chemistry*. Second Edition ed. Philadelphia: W.B. Saunders Company; 1994.
24. *The Merck Index*. Eleventh ed. NJ: Merck & Co., Inc.; 1989.

i-STAT is a trademark of the Abbott group of companies.

Vacutainer is a trademark of Becton Dickinson and Company, Franklin Lakes, NJ USA.

CX®3, LX20, CX9, Coulter S Plus are trademark of Beckman Coulter Incorporated, Fullerton, CA USA.

Ektachem was a trademark of Kodak Clinical Diagnostics. This system is now the Vitros® distributed by Ortho-Clinical Diagnostics, Rochester, NY, USA.

Stat Profile is a trademark of Nova Biomedical, Waltham, MA USA.


ICA 1 is a trademark of Radiometer Medical A/S, Copenhagen, Denmark.

The Bayer 860 analyzer is manufactured by Bayer Diagnostics, Tarrytown, NY USA.

Dimension RxL-Xpand is a trademark of Dade Behring Inc., Deerfield, IL USA.

Cell-Dyn is a trademark of Abbott Laboratories, Abbott Park, IL USA.

SE9500 is a trademark of Sysmex America Inc., Mundelein, IL USA.



©2019 Abbott Point of Care Inc. All rights reserved. Printed in USA.